Skip to main
AUTL

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics is anticipated to experience significant sales growth in 2026, with estimates reaching $167 million, representing an increase of approximately 220% year-over-year, well above consensus projections. The company's guidance for Aucatzyl also points towards solid performance, with expected sales between $120-135 million, reflecting about a 70% increase from the previous year. Additionally, with projected capital of around $370 million at the end of 2025, Autolus is well-positioned for expansion, enhancing its commercial prospects and overall valuation as it advances its innovative T-cell therapies.

Bears say

Autolus Therapeutics faced a challenging outlook due to disappointing revenue estimates for FY:26, which are projected at $120-135 million, falling short of previous expectations of $167 million. Additionally, early clinical results from the SLDAI-2K studies indicated limited efficacy in a small patient cohort, raising concerns about the future production of CAR-T therapeutics, which could impact overall revenue generation. These factors have led to a downward revision of estimates for FY:26 and FY:27, highlighting uncertainties surrounding the company's growth and market performance.

Autolus Therapeutics (AUTL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Autolus Therapeutics (AUTL) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.